Clinical trialsCompany release
Immutep reports 81% 12-month disease-free survival in neoadjuvant soft tissue sarcoma trial
IMMUTEP Ltd (IMMP) · Fri 20 Nov 2026
Phase II EFTISARC-NEO data presented at CTOS 2026 support eftilagimod alfa with pembrolizumab and radiotherapy, and Immutep plans a registration-directed study in the second half of 2027.
Immutep presented new survival data on 19 November 2026 from the investigator-initiated Phase II EFTISARC-NEO trial at the CTOS 2026 meeting. The study tests eftilagimod alfa (efti) combined with pembrolizumab and radiotherapy, given before surgery, in patients with high-risk resectable soft tissue sarcoma.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): IMMUTEP Ltd ↗
Article written by VigiEye from the official source (IMMUTEP Ltd). Claims are the company's own. AI-assisted; check the source before acting.
More Clinical trials
All →
PMV Pharma reports 48% response rate for rezatapopt in platinum-resistant ovarian cancer
🇺🇸 PMV Pharmaceuticals, Inc. (PMVP) · Fri 20 Nov 2026
J&J's Tremfya beats placebo in Phase 4 STAR axial psoriatic arthritis study at Week 24
Johnson & Johnson EMEA · Fri 20 Nov 2026
BfArM lists ArcRoyal field safety notice for procedure trays containing BD Connecta Stopcock
🇩🇪 BfArM field safety notices · Thu 19 Nov 2026
FDA allows Alpha Tau to double REGAIN glioblastoma trial to 20 patients
Alpha Tau Medical Ltd. (DRTS) · Thu 19 Nov 2026
Health Canada posts Type II recall of Philips Bridge Prep Kit over guidewire resistance
🇨🇦 Health Canada · Thu 19 Nov 2026
Olympus updates reprocessing instructions for GF-UC140P-AL5 endoscopic ultrasound gastrovideoscopes in Canada
🇨🇦 Health Canada · Thu 19 Nov 2026